Eculizumab for the treatment of two recurrences of atypical hemolytic uremic syndrome in a kidney allograft

Transplant International

Volumn 25, Issue 8, 2012, Pages

  Alachkar, Nada ^a   Bagnasco, Serena M ^a   Montgomery, Robert A ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BASILIXIMAB; CORTICOSTEROID; CYCLOSPORIN; ECULIZUMAB; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RAPAMYCIN; TACROLIMUS;

ADULT; CASE REPORT; DRUG MEGADOSE; FEMALE; HEMOLYTIC UREMIC SYNDROME; HUMAN; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY ALLOGRAFT; KIDNEY FAILURE; LETTER; PRIORITY JOURNAL; THROMBOCYTOPENIA;

ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; FEMALE; GRAFT REJECTION; HEMOLYTIC-UREMIC SYNDROME; HUMANS; KIDNEY TRANSPLANTATION; PLASMA EXCHANGE; RECURRENCE;

EID: 84863724130     PISSN: 09340874     EISSN: 14322277     Source Type: Journal    
DOI: 10.1111/j.1432-2277.2012.01497.x     Document Type: Letter

References (9)

1. Frémeaux-Bacchi V, Miller EC, Liszewski MK, et al. Mutations in complement C3 predispose to development of atypical hemolytic uremic syndrome. Blood 2008; 112: 4948.
2. Delvaeye M, Noris M, De Vriese A, et al. Thrombomodulin mutations in atypical hemolytic-uremic syndrome. N Engl J Med 2009; 361: 345.
3. Dragon-Durey M-A, Blanc C, Marliot F, et al. The high frequency of complement factor H related CFHR1 gene deletion is restricted to specific subgroups of patients with atypical haemolytic uraemic syndrome. J Med Genet 2009; 46: 447.
4. Benz K, Amann K,. Pathological aspects of membranoproliferative glomerulonephritis (MPGN) and haemolytic uraemic syndrome (HUS)/thrombocytic thrombopenic purpura (TTP). Thromb Haemost 2009; 101: 265.
5. Bresin E, Daina E, Noris M, et al. Outcome of renal transplantation in patients with non-Shiga toxin-associated hemolytic uremic syndrome: prognostic significance of genetic background. Clin J Am Soc Nephrol 2006; 1: 88.
6. Nürnberger J, Philipp T, Witzke O, et al. Eculizumab for atypical hemolytic-uremic syndrome. N Engl J Med 2009; 360: 542.
7. Zimmerhackl LB, Hofer J, Cortina G, et al. Prophylactic eculizumab after renal transplantation in atypical hemolytic-uremic syndrome. N Engl J Med 2010; 362: 1746.
8. Davin J-C, Gracchi V, Bouts A, Groothoff J, Strain L, Goodship T,. Maintenance of kidney function following treatment with eculizumab and discontinuation of plasma exchange after a third kidney transplant for atypical hemolytic uremic syndrome associated with a CFH mutation. Am J Kidney Dis 2010; 55: 708.
9. Nester C, Stewart Z, Myers D, et al. Pre-emptive eculizumab and plasmapheresis for renal transplant in atypical hemolytic uremic syndrome. Clin J Am Soc Nephrol 2011; 6: 1488.